Amneal Pharmaceuticals, Inc.
AMRX
$11.95
-$0.17-1.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 72.06M | 5.90M | 3.38M | -13.05M | -116.89M |
| Total Depreciation and Amortization | 223.57M | 240.48M | 245.36M | 240.82M | 236.19M |
| Total Amortization of Deferred Charges | 22.43M | 25.53M | 28.53M | 29.11M | 29.10M |
| Total Other Non-Cash Items | 226.45M | 226.22M | 150.68M | 148.51M | 150.77M |
| Change in Net Operating Assets | -204.52M | -170.37M | -76.87M | -98.47M | -4.07M |
| Cash from Operations | 339.99M | 327.76M | 351.08M | 306.92M | 295.10M |
| Capital Expenditure | -98.84M | -78.14M | -80.20M | -64.40M | -60.34M |
| Sale of Property, Plant, and Equipment | 2.09M | 1.38M | 1.38M | 524.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | 7.01M | 7.01M | 11.99M | 11.99M |
| Other Investing Activities | -15.51M | -13.11M | -9.30M | -9.15M | -14.65M |
| Cash from Investing | -112.26M | -82.87M | -81.12M | -61.03M | -63.00M |
| Total Debt Issued | 2.92B | 2.92B | 218.00M | 218.00M | 48.00M |
| Total Debt Repaid | -2.81B | -2.86B | -393.82M | -405.27M | -233.12M |
| Issuance of Common Stock | 1.96M | 1.56M | 1.52M | 1.20M | 1.15M |
| Repurchase of Common Stock | -22.28M | -22.34M | -22.41M | -22.38M | -7.95M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -118.82M | -119.23M | -37.70M | -19.35M | -19.88M |
| Cash from Financing | -31.53M | -82.61M | -234.40M | -227.80M | -211.79M |
| Foreign Exchange rate Adjustments | -1.68M | -2.21M | -1.51M | -1.30M | -999.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 194.52M | 160.06M | 34.05M | 16.78M | 19.31M |